

UPDATED VERSIONS OF EXINI BONE AND HEART, PRESENTED AT SSCPNM IN COPENHAGEN

EXINI Diagnostics AB (publ) will participate at the Congress of SSCPNM (Scandinavian Society of Clinical Physiology and Nuclear Medicine). The Congress will be held in Copenhagen in September 28 - 30. During the exhibition EXINI will present the latest version of EXINI bone™ with features such as calculation of the Bone Scan Index (BSI) and a unique module for CADx, that assesses whether the so-called "Hot spots" are pathological or not. EXINI's founder, Prof. Lars Edenbrandt, also conducts a plenary lecture during the scientific program at the Congress.

During SSCPNM in Copenhagen next week, EXINI will be attending both with its own stand during the exhibition as well as the scientific program. At the stand EXINI will show the latest versions of their products.

Interesting features of **EXINI bone™** are:

- Display of several studies on the same patient
- Automatic detection of hot spots
- Calculation of the Bone Scan Index (BSI), an imaging biomarker for prediction, treatment monitoring of patients with metastatic prostate cancer
- Unique CADx-module, assessing hot spots as pathological or not, and generates an automatic diagnostic advice.

EXINI will also show updated versions of:

- **EXINI heart™** for myocardscintigraf, the unique CADx-module that provides decision support in the form of an automatic diagnostic advice.
- **EXINI dat™** a quantification software that includes everything needed to report DaT SPECT scans.
- **EXINI brain™**, a quantification software for CBF-studies.

During the scientific program EXINI's founder, prof. Lars Edenbrandt, will conduct a plenary lecture, "Decision support systems in nuclear medicine: do They Work?"

For more information, please contact:

Magnus Aurell, CEO

Phone: +46 46-286 54 25

E-mail: magnus.aurell@exini.com

About EXINI Diagnostics AB (publ)

EXINI Diagnostics AB (publ) offers advanced solutions for medical decision support to hospitals worldwide. The system is based on advanced image analysis by artificial intelligence and can make their own interpretation of radiology images and providing diagnostic suggestions. In this way the system is used as a decision support for diagnosing sparkling doctor. EXINI is working on products for the diagnosis of some of the most frequent endemic diseases such as coronary heart disease, cancer, dementia and Parkinson's disease. Founded in 1999 by Professor Lars Edenbrandt and currently has 13 employees. EXINI is listed on the stock market square and has about 400 shareholders. Principal owner, Bo Håkansson.